{"ticker": {"uuid": "6c180d20-8da0-4454-85c4-602c9b980498", "symbol": "AVCT", "name": "Avacta Group Plc", "exchange": "LSE", "country": "GB", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Avacta Extends Cash Runway as Clinical Pipeline Advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPSFpNREUzTEVPWnQyTU50dXJtVTVRMmFzREFxQmZBRTd0S2gybmhkVGEtQ3EyWVNVNkVIbjB0OTk5WHo1eTdjaUJqZFNqZGZwZkE0MkNzdFg0cmhtdEg5dHFmbnFHY1V0bFk3OFRualZsU3VCV1A5dVRzM2ZpSDZ0UVgwVzZrdm1laE1LZA?oc=5", "source_name": "Share Talk", "published_at": "2026-06-22T06:29:33+00:00", "published_display": "22 Jun 2026 06:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Secures \u00a39m Fundraise to Reduce Debt Burden and Advance Cancer Drug Development (AVCT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOOTRfLTRhUy1uSVVGdW8wNWZja2QyZTFpaEktaE45T0dLLVFkQkJib0k0OW5ZRGRYUk9RTVJHcU15aldiRFhTT2lxU1AxYXNGUkhibGxWNmRCQThBWDBDMHFqYmtuZVZnTmJZSVdFQXpjdERORVRwX0ozQ0JDVlRtU0puMlNGZU5TeVlV?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "\u00a39m fundraising gives Avacta extra firepower for cancer pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNN2hYMnlvcGNsLWVjdWVnYnVVSGZNamVSOVBHS0EwTndXV0dXeXhmMkFock5ZWXdieHdJVkJvd3BsODdPZzhUcXh2MzYxQjZHelFNYkkxa2RQclJwVmxHQmwtenFQMlFZOXhob1RMRmtBQXcyTDI5c2d3NlN6Ylh0SVhkWXZrdlVJaWV1clZCT3ZSVElPU0E?oc=5", "source_name": "Share Talk", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta applies for block listing of 5.5 million shares on AIM", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPaTBPaTg4UGk0QmpOR2VwcjE1Q0E5ZWZZZlQzY0Q5M0FKd0hReUZzSFNKeDNkX3Z5dWJieVlPRDhIaGd6SVVyMnlqSW43MnJCZXdSUGpsejY5dUJfWmhucm9IYkhWR0paYkE4ZnFwNHlBS2FDcGlOcjhwOTUwNlRUVk9ZOEpMTFFyY21ON25NTFNMckduSkFPQlBfUHNEdEJKRjA0NnA3NmRvZE9xcVNabXJIWVpHbzF0Y3BzLXZB?oc=5", "source_name": "Investing.com UK", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Pre|CISION\u00ae payload release vs approved ADCs", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxORlRRUGxZdVc2QkI2YVJjbXc4RXVGelZyelVxMXIyU05IdVYycmJhVEQzamNJRTBkM3RFMmlrZHNYSFR2M3JJc2EyMFZ0d3JGZVpaOHNiVU9vS0RqMmIxRVVPMGNnSk42YnpUZ2xYbk9nc1haQTVpc3Focm9vTnlqUFhzMVhwZnZ1ZnJ2TG82VTEzS0RreGlVczBLWHRuZ3dh?oc=5", "source_name": "Share Talk", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Avacta data AACR underline AVA6103 profile", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOZ2ZHamZORXF1M0txb013ZDNwV2NGUzFERXduTllzVEVSQlVTRE5SODlPM1pWeWplbmRNODRoV21kaXhuVFZhbzlyeDBNaU9JWWtXSXE4UHF2SVIxcHJSZ09QdTE2aS03UVpOZ1pGV21LV29PeEZvX3JiRmhJZWhRV19kcG5FWlo1RkgtcjdILXp0eGl5ZGtKZ3pHUHdxeGhv?oc=5", "source_name": "Share Talk", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Christina Coughlin \u2013 In Vivo 2026 Rising Leader", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPQ0ZDeGtxTGZPWTZIMkkwWUYya1Z5cWtvZWpSMUxCRDVrMXBNc3VGNWFGbHlDV1gtbjhaQmpmWUo5UVpaZEs5dVBTRWxoS2d0cUhxQlAtejBGVW9tbmMwWEREeGljSl9VMk5wRmtSU00yZ2JTYUxORHVST01SY0xVQXl2MkxyTjBXZXFSZmJJdXEydlpYeHZ5eUlDRDhCYTh0eDZ4aA?oc=5", "source_name": "Share Talk", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Q1 2026 Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNcUoydGx3T21wZTJ6MVJOam10MEI5T2s5YnplSnFNd1E4YTNBWC1CREtxNFVMeUc5dGhXazNWS1BMODgwdkc2R1hmdkZnczdNR1FmTWlLcm1Tb0dFV0d5eXREanhSLXdVVHRhN1FoVVZVVzVRaHhoa21NeW5TbnhtcG1BNWN3MGc?oc=5", "source_name": "Share Talk", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Announces 2026 Science Day Event", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNZ0YxQmZYWGFOYUFFRmZHUHNzY3VoRFVockFhNktiNTVaQktLU0ZnUW4ydjNwXzJfQVQ0XzdUdEFKcG02bXhoc3NfZ0VBMkRHMDNEUUJkQk5IT3VMWXVhUUhTRU9sbDN0SVJDRWFpa1R1ZVZjQ3J4N0lmWWpzaUwxNnRHNExjQmFaWXNSdlAxRDlUUjQ?oc=5", "source_name": "Share Talk", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Result of Oversubscribed Fundraise", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQa1VoZ3h5RnYxOURzUk5SektCYldXdG5ZTENMTm9VT1J0TXZsdXFtTjdWQ0NCNGlYdW11TmJBMVMyMm1jOUZyS1dkeG5hSjlFRTlOMTMyRmUtdkxKSnJKME5YdDFMTHRyS2ZoM3dpcHJXd2tMVUdlVURNUFJ1RHNJaUdabXg4TUNSYVFJRGRnYjVHcEoxanc?oc=5", "source_name": "Share Talk", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Phase 1 study opening for AVA6103", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQZUQ4SjFWMnBfWDRqWnk4aEc2UTVFLTlYTmZBVTdKbklmNjlrVTNtbHhpVmNDdnlmZDVJeFhKaURvZldwRXNua1VteHBPYUNtcUNkV3lWVnFjaENRUzF4c0F1dHI2R2d3b3paNTNNcGI2X1dTdzRjcERkYjZ5VDFyNkZyZEZpLUxMTGY2MzdfNzdqWk1z?oc=5", "source_name": "Share Talk", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) PreCISION payload delivery advantage over ADC", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOcXFIc3lDYW9GWVE2QkZyeEg5THVDY2p0b2VJeTRwWVdhZ2NWVThKSW5ETUk5M096azkxdVdlSUhfNUw2V2huYjRSd3RmSzlzU2NOazd6M3NiSlh3V2cwTmVwbUhHb0RNY0RRWGtoRDhUWkdTZU5aaC1nX3U2NkdNemdrd3JnVkFkdW1mR2lLdmdpcGloWkg1aHZkM2pSbmpjZU5mMw?oc=5", "source_name": "Share Talk", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With 75% institutional ownership, Avacta Group Plc (LON:AVCT) is a favorite amongst the big guns", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOX3BCb3RRN0xnQlJ5LWN5TVhEbDVCQnJmQVczaFdOaFJucEVaZjZheGVIaGp2djZHSm8ycDRzMHlRQjhrTmFJN1BMQ2xpNjZOVTFmWnp3ZVZjMHpmb3hOakFQRlRZTlQyeVpfWXd1U0o0OVV4dENILWFFSjd3dHlkOF9NS3FTZmNvaExtc1Bn?oc=5", "source_name": "Market source", "published_at": "2026-02-15T08:00:00+00:00", "published_display": "15 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Appoints Francis Wilson as Chief Scientific Officer", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPc3Z6OXQ5S3FwOFpjNjExSkNuamg0M0p6ZFptbFBkS21HOEdPNlVsMGNfUWJubVFHNWhlaXl1RUVtTnY3UWNoOWthcFVlbmVoYkI1ckp2cEFYMXhKR3g3Z3dvcTAwQjlBV0Nla2VUS2hyRG9Rd1l1ZTluQ0Q1eUxCdnM0MVp3aXZrZUE2MVo3QkVNUEVOSGkzbDhzRktXTzdfR1EySUtVRXJMdEdI?oc=5", "source_name": "Share Talk", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Faridoxorubicin Program Clinical Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOQXlZaHZEcV94VkVoVWNkbTE1eHpzeGFVMWFJYllMdXIwS3h2dDgtYjhGaExPMDRiMkZka2wtclZmaHlMUHNkazE3aExVVTJhdnBNYmtJM0t4RUNvVG5BVUgwNm9HaWxVUllFVHdPSDJqcGJnOF9wb0UwZVJXdElsT0RtNFJGQ2dqeXNIcGw2YXVYN09QM3c4eDc1Nl9rQQ?oc=5", "source_name": "Share Talk", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) FDA Clearance of IND Application for AVA6103", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNM2VYZC1MRmE0Sl9RR21ka29RNGp1UEdwdW4xZ3FQeFVjXzdWc21DLXBBazl5MEpTb0dRMk1fR3ZIMGd3UkVmaVdhRGlSLW5wWmNUcFYweXJUeHYwOG1aOHo5dDdPRkcyUXdNNm5tY3FzWVJLZWRVd21HRU1NVWdiQUlMY0VlWmQ2RElEY1BhYzRTa19BTENidTFZa05CbEo0Nk1N?oc=5", "source_name": "Share Talk", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Group Plc FTSE AIM All Share Focused Update on Biotechnology Operations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOeFUySmo1TkF5enVpQWdXMGp3d0thWXd3cHRQVFBwUXFfTVV6OFFBbWVWcUtOWVJQblBwZHgwT2RvWEQwM001RXlkbEZKZVJmTzl2RU83MThTaUVubW10V1VPLXdSVU9GQTJpVURibVFUNnpibU0tTnVKM2U3bkR2YjVRajRtYnI5QVNwYi1zRE5wU0N4alBUV3ZVZmZOTzlGaVhON0xuZWktdzVtdUxkNXJqOGFfbWdkSHcwbF9RQ3M?oc=5", "source_name": "Kalkine Media", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Group Plc's (LON:AVCT) market cap decline of UK\u00a337m may not have as much of an impact on institutional owners after a year of 7.9% returns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) reports new AVA6103 pharmacology data", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxORHdwZXdwVENCOXNTSHRFOUF4eFdEbndQaWFYY1kxV0h1QkUwczIwWjJEZjI0akNldnBhUVcxWHNWdEpVSzF4ZnZYNGNKNUZCZDdacTYtNzBSZ3VCXzRmUTRON2VVWVdFaWpUc0ktUXQzRWtFeXU5YzJRYVlxVVAxVHNYNlFWNFhmVXNXWDhReWRWbGx4NjNWVUln?oc=5", "source_name": "Share Talk", "published_at": "2025-12-18T08:00:00+00:00", "published_display": "18 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Preliminary Data in Faridoxorubicin Phase 1b Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPSjBsTW1lTkZRYkNiQVIyeXVKcVFMeVRpV0hWZ1hDNk0xMERUbVNObEpVWTBBOUg3MlhReGdBSHhKQUJ3SlVDWjNoc0s1RVpRRXhpeEZWVXdIZmtQMFVfTTFRVUdCOFVqOTA5NDBFcjdZNmV5MjlQYmNUVVA1Vnk4RVZWZ1p0Ti16Wm5hU19iNWdQaV9SNXFaS0xCUEx2UXFFbGJwTDhRUm53WHM?oc=5", "source_name": "Share Talk", "published_at": "2025-12-08T08:00:00+00:00", "published_display": "08 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Shares \u2013 AVCT Price and Forecast", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTE1nemdjbTRfUUxTaE8xcWYwQWZnX1VsRHpQU2UwbjExbkRJWlRFbnE0LTY5X25WMTVOWU1sS0JJNmwwdndxSnpxWnM1WkFoak1ZUlNOT3NIQ3BaVS0xdmJROWxyUV9SMTVKODcw?oc=5", "source_name": "AskTraders", "published_at": "2024-07-23T19:17:07+00:00", "published_display": "23 Jul 2024 19:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVCT.L - Avacta Group plc Company Profile", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTFA1bDJhVlRJaWxxM1JvclpEVzZlSy00cklveG5GNExKSGxFRnoyd2thRkc5dFlKMkZFRGpFakNWeFl2QTV2WS1RaTF3?oc=5", "source_name": "StockInvest.us", "published_at": "2019-07-20T08:35:11+00:00", "published_display": "20 Jul 2019 08:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Group plc Ordinary 10p share price | AVCT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQdFJDUXQ5NVdUcklKUHZXOVlCdmpOREh2TWlzNmNUVkp4RlRzdlhiOVhLZ1ZLUUdacFpnc1dQTEtoZlN2ZEtXSEtrZnZIVE05XzJRbGR2anlTeDVyQkstMHBxMl8xZVdlUGFKYjFOYzg2NTl1SEFRdERycTBPRnpWbHNEdmNpSUlK?oc=5", "source_name": "Hargreaves Lansdown", "published_at": "2018-07-22T12:06:27+00:00", "published_display": "22 Jul 2018 12:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVCT Stock Price and Chart \u2014 LSE:AVCT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE1CNGJ0UXlxV1Etb2tzZ3QtOFVwMHdxQlhuaEZ2emx1amV6aWhwVlg3NWFQNWJDMG1NMlZjc3FfX3N6a09qOXJCb0lldmJuakVjSFZRLUVTeU8?oc=5", "source_name": "TradingView", "published_at": "2017-08-14T08:00:27+00:00", "published_display": "14 Aug 2017 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Group (AVCT) Share Price, Stock Value, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE1RdXBUci1GcE9IWm9CcmljQ0ZndWRibTZUT3Y3Rkt3cnVqNGhqaUhqY2NraVNldEZHczExSy1OU0VCejd2T05kQ25VZktxSklfMXo1a3dB?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-12T06:43:11+00:00", "published_display": "12 Aug 2016 06:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Avacta Extends Cash Runway as Clinical Pipeline Advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPSFpNREUzTEVPWnQyTU50dXJtVTVRMmFzREFxQmZBRTd0S2gybmhkVGEtQ3EyWVNVNkVIbjB0OTk5WHo1eTdjaUJqZFNqZGZwZkE0MkNzdFg0cmhtdEg5dHFmbnFHY1V0bFk3OFRualZsU3VCV1A5dVRzM2ZpSDZ0UVgwVzZrdm1laE1LZA?oc=5", "source_name": "Share Talk", "published_at": "2026-06-22T06:29:33+00:00", "published_display": "22 Jun 2026 06:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Secures \u00a39m Fundraise to Reduce Debt Burden and Advance Cancer Drug Development (AVCT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOOTRfLTRhUy1uSVVGdW8wNWZja2QyZTFpaEktaE45T0dLLVFkQkJib0k0OW5ZRGRYUk9RTVJHcU15aldiRFhTT2lxU1AxYXNGUkhibGxWNmRCQThBWDBDMHFqYmtuZVZnTmJZSVdFQXpjdERORVRwX0ozQ0JDVlRtU0puMlNGZU5TeVlV?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "\u00a39m fundraising gives Avacta extra firepower for cancer pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNN2hYMnlvcGNsLWVjdWVnYnVVSGZNamVSOVBHS0EwTndXV0dXeXhmMkFock5ZWXdieHdJVkJvd3BsODdPZzhUcXh2MzYxQjZHelFNYkkxa2RQclJwVmxHQmwtenFQMlFZOXhob1RMRmtBQXcyTDI5c2d3NlN6Ylh0SVhkWXZrdlVJaWV1clZCT3ZSVElPU0E?oc=5", "source_name": "Share Talk", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta applies for block listing of 5.5 million shares on AIM", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPaTBPaTg4UGk0QmpOR2VwcjE1Q0E5ZWZZZlQzY0Q5M0FKd0hReUZzSFNKeDNkX3Z5dWJieVlPRDhIaGd6SVVyMnlqSW43MnJCZXdSUGpsejY5dUJfWmhucm9IYkhWR0paYkE4ZnFwNHlBS2FDcGlOcjhwOTUwNlRUVk9ZOEpMTFFyY21ON25NTFNMckduSkFPQlBfUHNEdEJKRjA0NnA3NmRvZE9xcVNabXJIWVpHbzF0Y3BzLXZB?oc=5", "source_name": "Investing.com UK", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Pre|CISION\u00ae payload release vs approved ADCs", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxORlRRUGxZdVc2QkI2YVJjbXc4RXVGelZyelVxMXIyU05IdVYycmJhVEQzamNJRTBkM3RFMmlrZHNYSFR2M3JJc2EyMFZ0d3JGZVpaOHNiVU9vS0RqMmIxRVVPMGNnSk42YnpUZ2xYbk9nc1haQTVpc3Focm9vTnlqUFhzMVhwZnZ1ZnJ2TG82VTEzS0RreGlVczBLWHRuZ3dh?oc=5", "source_name": "Share Talk", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Avacta data AACR underline AVA6103 profile", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOZ2ZHamZORXF1M0txb013ZDNwV2NGUzFERXduTllzVEVSQlVTRE5SODlPM1pWeWplbmRNODRoV21kaXhuVFZhbzlyeDBNaU9JWWtXSXE4UHF2SVIxcHJSZ09QdTE2aS03UVpOZ1pGV21LV29PeEZvX3JiRmhJZWhRV19kcG5FWlo1RkgtcjdILXp0eGl5ZGtKZ3pHUHdxeGhv?oc=5", "source_name": "Share Talk", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Christina Coughlin \u2013 In Vivo 2026 Rising Leader", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPQ0ZDeGtxTGZPWTZIMkkwWUYya1Z5cWtvZWpSMUxCRDVrMXBNc3VGNWFGbHlDV1gtbjhaQmpmWUo5UVpaZEs5dVBTRWxoS2d0cUhxQlAtejBGVW9tbmMwWEREeGljSl9VMk5wRmtSU00yZ2JTYUxORHVST01SY0xVQXl2MkxyTjBXZXFSZmJJdXEydlpYeHZ5eUlDRDhCYTh0eDZ4aA?oc=5", "source_name": "Share Talk", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Q1 2026 Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNcUoydGx3T21wZTJ6MVJOam10MEI5T2s5YnplSnFNd1E4YTNBWC1CREtxNFVMeUc5dGhXazNWS1BMODgwdkc2R1hmdkZnczdNR1FmTWlLcm1Tb0dFV0d5eXREanhSLXdVVHRhN1FoVVZVVzVRaHhoa21NeW5TbnhtcG1BNWN3MGc?oc=5", "source_name": "Share Talk", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Announces 2026 Science Day Event", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNZ0YxQmZYWGFOYUFFRmZHUHNzY3VoRFVockFhNktiNTVaQktLU0ZnUW4ydjNwXzJfQVQ0XzdUdEFKcG02bXhoc3NfZ0VBMkRHMDNEUUJkQk5IT3VMWXVhUUhTRU9sbDN0SVJDRWFpa1R1ZVZjQ3J4N0lmWWpzaUwxNnRHNExjQmFaWXNSdlAxRDlUUjQ?oc=5", "source_name": "Share Talk", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Result of Oversubscribed Fundraise", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQa1VoZ3h5RnYxOURzUk5SektCYldXdG5ZTENMTm9VT1J0TXZsdXFtTjdWQ0NCNGlYdW11TmJBMVMyMm1jOUZyS1dkeG5hSjlFRTlOMTMyRmUtdkxKSnJKME5YdDFMTHRyS2ZoM3dpcHJXd2tMVUdlVURNUFJ1RHNJaUdabXg4TUNSYVFJRGRnYjVHcEoxanc?oc=5", "source_name": "Share Talk", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Phase 1 study opening for AVA6103", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQZUQ4SjFWMnBfWDRqWnk4aEc2UTVFLTlYTmZBVTdKbklmNjlrVTNtbHhpVmNDdnlmZDVJeFhKaURvZldwRXNua1VteHBPYUNtcUNkV3lWVnFjaENRUzF4c0F1dHI2R2d3b3paNTNNcGI2X1dTdzRjcERkYjZ5VDFyNkZyZEZpLUxMTGY2MzdfNzdqWk1z?oc=5", "source_name": "Share Talk", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) PreCISION payload delivery advantage over ADC", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOcXFIc3lDYW9GWVE2QkZyeEg5THVDY2p0b2VJeTRwWVdhZ2NWVThKSW5ETUk5M096azkxdVdlSUhfNUw2V2huYjRSd3RmSzlzU2NOazd6M3NiSlh3V2cwTmVwbUhHb0RNY0RRWGtoRDhUWkdTZU5aaC1nX3U2NkdNemdrd3JnVkFkdW1mR2lLdmdpcGloWkg1aHZkM2pSbmpjZU5mMw?oc=5", "source_name": "Share Talk", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With 75% institutional ownership, Avacta Group Plc (LON:AVCT) is a favorite amongst the big guns", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOX3BCb3RRN0xnQlJ5LWN5TVhEbDVCQnJmQVczaFdOaFJucEVaZjZheGVIaGp2djZHSm8ycDRzMHlRQjhrTmFJN1BMQ2xpNjZOVTFmWnp3ZVZjMHpmb3hOakFQRlRZTlQyeVpfWXd1U0o0OVV4dENILWFFSjd3dHlkOF9NS3FTZmNvaExtc1Bn?oc=5", "source_name": "Market source", "published_at": "2026-02-15T08:00:00+00:00", "published_display": "15 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Appoints Francis Wilson as Chief Scientific Officer", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPc3Z6OXQ5S3FwOFpjNjExSkNuamg0M0p6ZFptbFBkS21HOEdPNlVsMGNfUWJubVFHNWhlaXl1RUVtTnY3UWNoOWthcFVlbmVoYkI1ckp2cEFYMXhKR3g3Z3dvcTAwQjlBV0Nla2VUS2hyRG9Rd1l1ZTluQ0Q1eUxCdnM0MVp3aXZrZUE2MVo3QkVNUEVOSGkzbDhzRktXTzdfR1EySUtVRXJMdEdI?oc=5", "source_name": "Share Talk", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Faridoxorubicin Program Clinical Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOQXlZaHZEcV94VkVoVWNkbTE1eHpzeGFVMWFJYllMdXIwS3h2dDgtYjhGaExPMDRiMkZka2wtclZmaHlMUHNkazE3aExVVTJhdnBNYmtJM0t4RUNvVG5BVUgwNm9HaWxVUllFVHdPSDJqcGJnOF9wb0UwZVJXdElsT0RtNFJGQ2dqeXNIcGw2YXVYN09QM3c4eDc1Nl9rQQ?oc=5", "source_name": "Share Talk", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) FDA Clearance of IND Application for AVA6103", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNM2VYZC1MRmE0Sl9RR21ka29RNGp1UEdwdW4xZ3FQeFVjXzdWc21DLXBBazl5MEpTb0dRMk1fR3ZIMGd3UkVmaVdhRGlSLW5wWmNUcFYweXJUeHYwOG1aOHo5dDdPRkcyUXdNNm5tY3FzWVJLZWRVd21HRU1NVWdiQUlMY0VlWmQ2RElEY1BhYzRTa19BTENidTFZa05CbEo0Nk1N?oc=5", "source_name": "Share Talk", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Group Plc FTSE AIM All Share Focused Update on Biotechnology Operations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOeFUySmo1TkF5enVpQWdXMGp3d0thWXd3cHRQVFBwUXFfTVV6OFFBbWVWcUtOWVJQblBwZHgwT2RvWEQwM001RXlkbEZKZVJmTzl2RU83MThTaUVubW10V1VPLXdSVU9GQTJpVURibVFUNnpibU0tTnVKM2U3bkR2YjVRajRtYnI5QVNwYi1zRE5wU0N4alBUV3ZVZmZOTzlGaVhON0xuZWktdzVtdUxkNXJqOGFfbWdkSHcwbF9RQ3M?oc=5", "source_name": "Kalkine Media", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Group Plc's (LON:AVCT) market cap decline of UK\u00a337m may not have as much of an impact on institutional owners after a year of 7.9% returns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) reports new AVA6103 pharmacology data", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxORHdwZXdwVENCOXNTSHRFOUF4eFdEbndQaWFYY1kxV0h1QkUwczIwWjJEZjI0akNldnBhUVcxWHNWdEpVSzF4ZnZYNGNKNUZCZDdacTYtNzBSZ3VCXzRmUTRON2VVWVdFaWpUc0ktUXQzRWtFeXU5YzJRYVlxVVAxVHNYNlFWNFhmVXNXWDhReWRWbGx4NjNWVUln?oc=5", "source_name": "Share Talk", "published_at": "2025-12-18T08:00:00+00:00", "published_display": "18 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Therapeutics (AIM: AVCT) Preliminary Data in Faridoxorubicin Phase 1b Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPSjBsTW1lTkZRYkNiQVIyeXVKcVFMeVRpV0hWZ1hDNk0xMERUbVNObEpVWTBBOUg3MlhReGdBSHhKQUJ3SlVDWjNoc0s1RVpRRXhpeEZWVXdIZmtQMFVfTTFRVUdCOFVqOTA5NDBFcjdZNmV5MjlQYmNUVVA1Vnk4RVZWZ1p0Ti16Wm5hU19iNWdQaV9SNXFaS0xCUEx2UXFFbGJwTDhRUm53WHM?oc=5", "source_name": "Share Talk", "published_at": "2025-12-08T08:00:00+00:00", "published_display": "08 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Shares \u2013 AVCT Price and Forecast", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTE1nemdjbTRfUUxTaE8xcWYwQWZnX1VsRHpQU2UwbjExbkRJWlRFbnE0LTY5X25WMTVOWU1sS0JJNmwwdndxSnpxWnM1WkFoak1ZUlNOT3NIQ3BaVS0xdmJROWxyUV9SMTVKODcw?oc=5", "source_name": "AskTraders", "published_at": "2024-07-23T19:17:07+00:00", "published_display": "23 Jul 2024 19:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVCT.L - Avacta Group plc Company Profile", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTFA1bDJhVlRJaWxxM1JvclpEVzZlSy00cklveG5GNExKSGxFRnoyd2thRkc5dFlKMkZFRGpFakNWeFl2QTV2WS1RaTF3?oc=5", "source_name": "StockInvest.us", "published_at": "2019-07-20T08:35:11+00:00", "published_display": "20 Jul 2019 08:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Group plc Ordinary 10p share price | AVCT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQdFJDUXQ5NVdUcklKUHZXOVlCdmpOREh2TWlzNmNUVkp4RlRzdlhiOVhLZ1ZLUUdacFpnc1dQTEtoZlN2ZEtXSEtrZnZIVE05XzJRbGR2anlTeDVyQkstMHBxMl8xZVdlUGFKYjFOYzg2NTl1SEFRdERycTBPRnpWbHNEdmNpSUlK?oc=5", "source_name": "Hargreaves Lansdown", "published_at": "2018-07-22T12:06:27+00:00", "published_display": "22 Jul 2018 12:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVCT Stock Price and Chart \u2014 LSE:AVCT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE1CNGJ0UXlxV1Etb2tzZ3QtOFVwMHdxQlhuaEZ2emx1amV6aWhwVlg3NWFQNWJDMG1NMlZjc3FfX3N6a09qOXJCb0lldmJuakVjSFZRLUVTeU8?oc=5", "source_name": "TradingView", "published_at": "2017-08-14T08:00:27+00:00", "published_display": "14 Aug 2017 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avacta Group (AVCT) Share Price, Stock Value, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE1RdXBUci1GcE9IWm9CcmljQ0ZndWRibTZUT3Y3Rkt3cnVqNGhqaUhqY2NraVNldEZHczExSy1OU0VCejd2T05kQ25VZktxSklfMXo1a3dB?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-12T06:43:11+00:00", "published_display": "12 Aug 2016 06:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 79, "total_relevant": 25, "sentiment_summary": {"positive": 0, "negative": 1, "neutral": 24, "score": 49, "total": 25, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 91, "events": [{"event": "general", "label": "Market update", "weight": 12.1, "count": 22}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 73.0, "latest_week": "2026-06-19", "one_week_move": 2.8, "four_week_move": -7.6, "twelve_week_move": 12.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.060803, "market_dynamics_buy_signal": false, "relative_strength": 10.747391, "fair_value_gap": 5.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 39.3393, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.8% over one week, -7.6% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Share Talk", "count": 15}, {"label": "Market source", "count": 2}, {"label": "Investing.com UK", "count": 1}, {"label": "Kalkine Media", "count": 1}, {"label": "simplywall.st", "count": 1}, {"label": "AskTraders", "count": 1}, {"label": "StockInvest.us", "count": 1}, {"label": "Hargreaves Lansdown", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 25}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 22}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "49/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "91/100 classification confidence."}, {"label": "Company focus", "value": "25", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+2.8% over one week, -7.6% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Avacta Extends Cash Runway as Clinical Pipeline Advances"}], "updated_at": "2026-06-22T20:06:51.722748+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}